08:58 AM EDT, 06/27/2025 (MT Newswires) -- Omeros ( OMER ) said Friday that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
The review procedure begins in mid-July, with a final decision expected in mid-2026, the company said.